Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

Bibliographic Details
Main Authors: Berruti, Alfredo, Fazio, Nicola, Ferrero, Anna, Brizzi, Maria Pia, Volante, Marco, Nobili, Elisabetta, Tozzi, Lucia, Bodei, Lisa, Torta, Mirella, D’Avolio, Antonio, Priola, Adriano Massimiliano, Birocco, Nadia, Amoroso, Vito, Biasco, Guido, Papotti, Mauro, Dogliotti, Luigi
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996907/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996907/

Similar Items